WO1997032832A1 - Process for producing fluorinated aromatics and fluorinated nitrogen-containing hetero-aromatics - Google Patents
Process for producing fluorinated aromatics and fluorinated nitrogen-containing hetero-aromatics Download PDFInfo
- Publication number
- WO1997032832A1 WO1997032832A1 PCT/EP1997/000970 EP9700970W WO9732832A1 WO 1997032832 A1 WO1997032832 A1 WO 1997032832A1 EP 9700970 W EP9700970 W EP 9700970W WO 9732832 A1 WO9732832 A1 WO 9732832A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radicals
- alkyl
- formula
- general formula
- compound
- Prior art date
Links
- 0 CP1(C(*)=C(*)C(*)(*)C1(*)*)=O Chemical compound CP1(C(*)=C(*)C(*)(*)C1(*)*)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B39/00—Halogenation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
Definitions
- the invention relates to a process for the preparation of fluorinated aromatic compounds of the general formula I.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 the same or different, hydrogen, F, Cl, Br, J, NO 2 , CF 3 , CN, CHO, COF, SO 2 F, SO 2 CI, OCF 3 , SCF 3 , SO 2 CF 3 , COOR 7 , CONR 8 R 9 , SO 2 R 10 , COR 1 1 or OR 12 or two residues from the group R 1 to R 6 located in the ortho position to one another together are -OC-NR 13 -CO-,
- R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 the same or different, independently of one another, hydrogen, C 1 -C 6 -alkyl, linear or branched, aryl, preferably phenyl, or arylalkyl, and both the alkyl radicals and the arylalkyl radicals can optionally be substituted up to three times with halogen, preferably CF 3 and CHal x H 3 .
- x can be, and optionally two or more of the radicals R 1 to R 13 are joined together to form one or more rings, it being possible for the ring or rings to have 3 to 7 ring members,
- MeF (II) where Me is Na, K, Cs, Rb, N (R 14 ) 4 or P (R 15 ) 4 ,
- R 14 radicals independently of one another, may be the same or different hydrogen, C 1 -C 8 -alkyl, linear or branched, the alkyl radicals in turn being able to be substituted, for example, with aromatic radicals; and the four R 15 radicals, independently of one another, the same or different, can have the meaning of R 14 and can also be phenyl; in a reaction medium.
- the substitution of aromatically bound hydrogen by fluorine is of great importance for the synthesis of bioactive substances or for the preparation of precursors to such compounds. Furthermore, it is well known that fluorine has strong and often unexpected effects on the biological activity of chemical compounds. The exchange of hydrogen for fluorine in a biologically active molecule often leads to an analogue compound with an increased or modified biological effect.
- Patents and publications D1 to D5 generally describe the production of fluoroaromatics by directly exchanging halogen atoms with KF, CsF or (Alk) 4 N + F " .
- KF KF
- CsF CsF
- Alk Alk
- F Industrial time only used KF.
- its use has a number of serious disadvantages.
- the solubility of KF in most aprotic organic solvents is generally very low and is in the range of about 10 "3 mol / l or less. This means a low concentration of fluoride ions in solution and leads to de facto long reaction times, one high energy consumption and high equipment costs, and there is also a need to work at high temperatures, which often leads to the formation of by-products.
- the Cl-F exchange usually takes place at activated aromatics at temperatures in the range of about 100 to 200 ° C and at non-activated aromatics at temperatures in the range of about 250 to 400 ° C.
- slightly or not activated aromatics particularly drastic reaction conditions are necessary (cf. D10), with numerous by-products being formed.
- the reactions can be carried out in a solvent or without solvent. However, the best results can be achieved using aprotic, highly polar solvents as the reaction medium.
- Acetonitrile (CH 3 CN), dimethylformamide (DMFA), dimethylacetamide (DMAA), N-methylpyrrolidone (NMP), dimethyl sulfoxide (DMSO), tetramethylene sulfone (sulfolane or TMS), hexamethylphosphoric triamide (HMPA), pyridylonitrile (pyridylonitrile) were used as solvents (PhCN) used.
- the rate of fluorination with KF on the same substrate increases depending on the solvent as follows: acetonitrile (CH 3 CN) - N-methylpyrrolidone (NMP) - tetramethylene sulfone (sulfolane) - dimethyl sulfoxide (DMSO) (see D6).
- HMPA HMPA shows excellent properties as a solvent for Halex reactions, but because of its toxicity for industrial processes it is out of the question.
- R 16 is an alkyl radical with 1 to 8 carbon atoms, which can be linear or branched, phenyl, benzyl, cycloalkyl, OR 25 or NR 26 R 27 , where R 25 to R 27, independently of one another, identically or differently, are an alkyl radical with 1 mean up to 4 carbon atoms, which can be linear or branched, and
- R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 independently of one another, identically or differently, denote hydrogen, phenyl or a C 1-6 alkyl radical, linear or branched,
- the method of the invention has the following advantages.
- the compounds of the general formulas III to V are high-boiling, thermally stable, non-toxic or only slightly toxic liquids.
- solubility of, for example, KF in reaction media of the general formulas III to V is substantially better, especially at elevated temperatures, than in TMS, NMP, DMAA and comparable to DMSO, so that the fluorination of aromatics takes place completely without any great technical effort by means of halogen exchange and the response time and energy consumption are reduced
- the compounds of the general formulas III to V cover a broad spectrum of boiling points, so that by selecting a suitable compound depending on the boiling point of the expected target product, in almost all cases the reaction mixture can be worked up after the fluorination by separating the reaction mixture by distillation .
- the compounds of the general formulas III to V can already provide these advantages if they are present in reaction media for the Halex reaction. That is, they are an addition to an otherwise common reaction medium for fluorination by halogen exchange. In this way, the advantages of the invention can already be achieved.
- the proportion of compound of the general formulas III to V is variable, since even small additives are able to ensure a positive influence on the Halex reaction.
- the proportion of compounds of the general formulas III to V which is present in the reaction medium according to the invention is preferably 1.0 to 100 mol%, in particular 5.0 to 80 mol% and particularly preferably 10 to 60 mol%, based on the compound corresponding to formula I, but in which the radical R 1 to R 6 which is fluorine in formula I is Cl or Br.
- a proportion of more than 50% by weight (wt / wt) based on the total weight of the reaction medium is particularly expedient.
- the 1-alkyl-2,3-dihydro-1 H-phosphol-1-oxides of the general formula III, 1-alkyl-2,5-dihydro-1 H-phosphol-1-oxides, which are suitable according to the invention as diluents or solvents of the general formula IV and / or 1-alkylphospholan-1-oxides of the general formula V are for the most part commercially available and thus available.
- Compounds of the general formulas III to V which are not commercially available can be synthesized in a simple manner by processes familiar to the person skilled in the art. Examples of syntheses can be found, inter alia, in DE-A 2826621 or DE-A 35 14451.
- reaction media mentioned can be used as a diluent, solvent or additive to such agents.
- the compounds according to the invention can be used in pure form or in a mixture of more than one compound.
- the various compounds belonging to the general formulas III to V have different boiling points. Depending on the boiling point of the aromatic starting materials and products and depending on the desired product work-up, a compound tailored to each individual case or an optimal mixture of several compounds of the formulas III to V can be selected, be it as an additive to other reaction media or as a pure reaction medium Form or in a mixture.
- Particularly preferred among the compounds of the general formulas III to V in the context of the invention are 1-methyl-2,3-dihydro-1 H-phosphol-1-oxide (same as purple), 1-methyl-2,5-dihydro- 1 H-phosphol-1-oxide (same as compound IVa) and / or 1-methyl-phospholan-1-oxide (same as compound Va), ie it is advantageous Fluorination is carried out by halogen exchange in one or more compounds of the general formulas III, IV and / or V, in which R 16 is methyl and R 17 to R 24 are hydrogen.
- the process according to the invention is further modified in such a way that the fluorination is carried out by halogen exchange in 1-alkylphospholan-1-oxides of the general formula V; 1-methyl-phospholan-1-oxide (same as compound Va).
- the process according to the invention is applicable to a large number of compounds corresponding to the general formula I, in which case also substrates which include structures of the formula I as an aromatic subunit in a larger molecule are to be counted.
- R 1 'to R 5' the same or different, hydrogen, F, Cl, Br, J, NO 2 , CF 3 , CN, CHO, COF, SO 2 F, SO 2 CI, OCF 3 , SCF 3 , SO 2 CF.
- R 1 ' to R 4' the same or different, hydrogen, F, Cl, Br, J, NO 2 , CF 3 , CN, CHO, COF, SO 2 F, SO 2 CI, OCF 3 , SCF 3 , SO 2 CF.
- R 1 ' to R 4' have the same meaning as in formula VIII and shark stands for Cl or Br.
- the process according to the invention can also be used to prepare compounds of the general formula X, XI and XII or XIII
- R 1 ' to R 3' are the same or different, hydrogen, F, Cl, Br, J, NO 2 , CF 3 , CN, CHO, COF, SO 2 F, SO 2 CI, OCF 3 , SCF 3 , SO 2 CF. 3 , COOR 7 , CONR 8 R 9 , SO 2 R 10 , COR 11 or OR 12 or, where possible, two radicals from the group R 1 ' to R 3' located in the ortho position to one another together -OC-NR 13 Are -CO-, with R 7 to R 13 as in formula I,
- R 1 ' to R 3' have the meaning given in the formulas X to XIII and shark stands for Cl or Br.
- the fluorination by halogen exchange is carried out at temperatures in the range from about room temperature to the boiling point of the reaction medium or the starting materials, which correspond to compounds of the general formula I, depending on which boiling point is lower .
- temperatures can usually be kept lower without sacrificing the speed of the reaction.
- the Halex process according to the invention is characterized in that the fluorination is carried out by halogen exchange at temperatures in the range from about 40 ° C. to about 270 ° C. In a particularly preferred modification, the reaction temperatures are in the range from about 60 ° C. to about 220 ° C.
- the fluorinating agents which can be used according to the invention basically include all compounds of the formula II (MeF) in which Me represents an alkali metal, ammonium, phosphonium or an alkylammonium or alkyl or arylphosphonium radical derived from ammonium or phosphonium.
- Me represents an alkali metal, ammonium, phosphonium or an alkylammonium or alkyl or arylphosphonium radical derived from ammonium or phosphonium.
- Compounds such as sodium fluoride, potassium fluoride, cesium fluoride, tetramethylammonium fluoride and other tetraalkylammonium fluorides in which Alkyl represents ethyl, n-propyl, n-butyl. Tetraphenylphosphoium fluoride is also particularly useful.
- potassium fluoride is particularly preferred because of its low price.
- the fluorinating agents are used in an amount sufficient to achieve the desired level of halogen exchange. Their stoichiometric use is preferred, based on the amount of the starting compound which corresponds to the compound of the formula I. Use in excess is also preferred, particularly preferably 1.1 to 2.0 times the molar amount based on the mol of the halogen atoms to be replaced in the starting compound or compounds.
- the efficiency of the reaction media used according to the invention can optionally be further improved by adding catalytically active compounds. In general, all the expert can do this for. B. from the references cited known catalysts.
- the catalysts which can be used include (R “ ) 4 N + Hal " with shark equal to Cl or Br and R “ equal to C r C 4 alkyl, linear or branched; (R '" ) 4 P + Hal " with shark equal Cl or Br and R '" equal to C r C 4 alkyl, linear or branched, or aryl, preferably phenyl; Crown ether; Polyethylene glycols and / or pyridinium salts.
- the process of the invention is particularly advantageous with the addition of catalytically effective amounts of tetramethylammonium chloride, tetrabutylammonium chloride, tetraphenylphosphonium bromide, 18-crown-6, PEG and / or R 28 R 29 Np-pyridinium-R 30 , in which R 28 to R 30 preferably an alkyl radical mean with 1 to 8 carbon atoms, which can be linear or branched.
- the work-up of the reaction mixture after the fluorination can, as already indicated, advantageously be carried out by separating the reaction mixture by distillation and enables the solvents to be isolated and recycled.
- the mixture is poured into an excess of water and the products obtained are filtered off or extracted with organic solvents.
- the extraction of the compounds of the general formulas III to V can be carried out in a simple manner and completely from reaction solutions in perforators continuously with dichloromethane or trichloromethane.
- the desired target products are obtained with extraordinary purity.
- products with a degree of purity of the crude product> 90% are generally available according to the procedure described here. It is noteworthy, for example, that, apart from the compounds of the general formulas III to V, it is hardly possible to extract any impurities and that, after the solvent has been stripped off, crude products which are> 95% pure are obtained.
- the invention also relates to the use of 1-alkyl-2,3-dihydro-1H-phosphol-1-oxides of the general formula III, 1-alkyl-2,5-dihydro-1H-phosphol-1-oxides of the general formula IV and / or 1-alkyl-phospholan-1-oxides of the general formula V,
- R 16 is an alkyl radical with 1 to 8 carbon atoms, which can be linear or branched, phenyl, Is benzyl, cycloalkyl, OR 25 or NR 26 R 27 , where R 25 to R 27, independently of one another, identically or differently, denote an alkyl radical having 1 to 4 carbon atoms, which may be linear or branched, and
- R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 independently of one another, identically or differently, denote hydrogen, phenyl or a C 1-4 alkyl radical, linear or branched,
- reaction medium as a reaction medium, diluent, solvent or addition to such media and agents to the starting compounds in the preparation of fluorinated aromatic compounds of the general formula I.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 the same or different, hydrogen, F, Cl, Br, J, NO 2 , CF 3 , CN, CHO, COF, SO 2 F, SO 2 CI, OCF 3 , SCF 3 , SO 2 CF 3 , COOR 7 , CONR 8 R 9 , SO 2 R 10 , COR 11 or OR 12 are together or two residues from the group R 1 to R 6 which are in the ortho-position to one another -OC-NR 13 -CO-,
- R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 the same or different, independently of one another hydrogen, C r C 6 alkyl, linear or branched, aryl, preferably phenyl, or arylalkyl , and both the alkyl radicals and the arylalkyl radicals can optionally be substituted up to three times with halogen, where they can preferably be CF 3 and CHal x H 3.x , and
- radicals R 1 to R 13 are joined together to form one or more rings, it being possible for the ring or rings to have 3 to 7 ring members,
- the remaining radicals from the group R 1 to R 6 may all be hydrogen
- R 14 radicals independently of one another, may be the same or different hydrogen, C 1 -C 8 -alkyl, linear or branched, the alkyl radicals in turn being able to be substituted, for example, with aromatic radicals; and the four radicals R 15 , independently of one another, the same or different, have the meaning of R 14 and can also be phenyl.
- reaction mixture was poured into an excess of water and the solid constituents were filtered off, optionally extracted with CH 2 Cl 2 to obtain liquid products, washed with water and dried.
- product mixture obtained can be analyzed with GC, GCMS and 19 F NMR.
- the products are further purified by recrystallization from suitable solvents or fractional distillation at atmospheric pressure or under reduced pressure.
- Table 1 gives an overview of the substrates used in the examples, which were used for fluorination by halogen exchange Reaction media, the further reaction conditions, the conversion and the yield of the overall product.
- Tetraphenylphosphonium as catalyst Cf. 12a * comparative example taken from D14 Example 15
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9531421A JP2000506149A (en) | 1996-03-07 | 1997-02-28 | Preparation of fluorinated aromatic compounds and fluorinated nitrogen-containing heterocyclic aromatic compounds |
EP97905116A EP0885179A1 (en) | 1996-03-07 | 1997-02-28 | Process for producing fluorinated aromatics and fluorinated nitrogen-containing hetero-aromatics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19608791A DE19608791A1 (en) | 1996-03-07 | 1996-03-07 | Process for the preparation of fluorinated aromatics and fluorinated nitrogen-containing heteroaromatics |
DE19608791.0 | 1996-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997032832A1 true WO1997032832A1 (en) | 1997-09-12 |
Family
ID=7787475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/000970 WO1997032832A1 (en) | 1996-03-07 | 1997-02-28 | Process for producing fluorinated aromatics and fluorinated nitrogen-containing hetero-aromatics |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0885179A1 (en) |
JP (1) | JP2000506149A (en) |
KR (1) | KR19990087687A (en) |
CN (1) | CN1212674A (en) |
CA (1) | CA2248294A1 (en) |
DE (1) | DE19608791A1 (en) |
WO (1) | WO1997032832A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998022413A1 (en) * | 1996-11-22 | 1998-05-28 | Albemarle Corporation | Halogen exchange reactions and uses thereof |
EP1070724A1 (en) * | 1999-07-23 | 2001-01-24 | Clariant GmbH | Mixtures comprising tetrakis(pyrrolidino/piperidino)phosphonium salts |
US7514456B2 (en) | 2002-02-12 | 2009-04-07 | Smithkline Beecham Corporation | Nicotinamide derivatives useful as p38 inhibitors |
US7626055B2 (en) | 2003-04-09 | 2009-12-01 | Smithkline Beecham Corporation | Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors |
US9266886B2 (en) | 2014-02-03 | 2016-02-23 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9796710B2 (en) | 2014-10-14 | 2017-10-24 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
US10829481B2 (en) | 2016-01-29 | 2020-11-10 | Vitae Pharmaceuticals, Llc | Benzimidazole derivatives as modulators of ROR-gamma |
US10913739B2 (en) | 2017-07-24 | 2021-02-09 | Vitae Pharmaceuticals, LLC (121374) | Inhibitors of RORγ |
US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
US11186573B2 (en) | 2017-07-24 | 2021-11-30 | Vitae Pharmaceuticals, Llc | Inhibitors of ROR gamma |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004033525A1 (en) * | 2004-07-08 | 2006-02-02 | Lanxess Deutschland Gmbh | Improved process for the production of ring-fluorinated aromatics |
CN115745766A (en) * | 2022-10-27 | 2023-03-07 | 兰州康鹏威耳化工有限公司 | Preparation method of trifluorobenzaldehyde and trifluorobenzyl bromide |
CN115611717A (en) * | 2022-11-01 | 2023-01-17 | 上海万溯药业有限公司 | Preparation method of polyfluorobenzaldehyde |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2525442A1 (en) * | 1975-06-07 | 1976-12-09 | Bayer Ag | PROCESS FOR PRODUCING GEMINAL DIHALOGENIDE |
EP0523671A2 (en) * | 1991-07-17 | 1993-01-20 | Hoechst Aktiengesellschaft | Process for the preparation of chlorofluoronitrobenzenes |
US5315043A (en) * | 1992-02-05 | 1994-05-24 | E. I. Du Pont De Nemours And Company | Aromatic nucleophilic fluorination |
-
1996
- 1996-03-07 DE DE19608791A patent/DE19608791A1/en not_active Withdrawn
-
1997
- 1997-02-28 EP EP97905116A patent/EP0885179A1/en not_active Withdrawn
- 1997-02-28 KR KR1019980707152A patent/KR19990087687A/en not_active Application Discontinuation
- 1997-02-28 CA CA002248294A patent/CA2248294A1/en not_active Abandoned
- 1997-02-28 JP JP9531421A patent/JP2000506149A/en active Pending
- 1997-02-28 CN CN97192773A patent/CN1212674A/en active Pending
- 1997-02-28 WO PCT/EP1997/000970 patent/WO1997032832A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2525442A1 (en) * | 1975-06-07 | 1976-12-09 | Bayer Ag | PROCESS FOR PRODUCING GEMINAL DIHALOGENIDE |
EP0523671A2 (en) * | 1991-07-17 | 1993-01-20 | Hoechst Aktiengesellschaft | Process for the preparation of chlorofluoronitrobenzenes |
US5315043A (en) * | 1992-02-05 | 1994-05-24 | E. I. Du Pont De Nemours And Company | Aromatic nucleophilic fluorination |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998022413A1 (en) * | 1996-11-22 | 1998-05-28 | Albemarle Corporation | Halogen exchange reactions and uses thereof |
CN1122004C (en) * | 1996-11-22 | 2003-09-24 | 阿尔伯麦尔公司 | Halogen exchange reactions and uses thereof |
EP1070724A1 (en) * | 1999-07-23 | 2001-01-24 | Clariant GmbH | Mixtures comprising tetrakis(pyrrolidino/piperidino)phosphonium salts |
US6407029B1 (en) | 1999-07-23 | 2002-06-18 | Clariant Gmbh | Mixtures comprising tetrakis(pyrrolidino/piperdino)phosphonium salts |
US7514456B2 (en) | 2002-02-12 | 2009-04-07 | Smithkline Beecham Corporation | Nicotinamide derivatives useful as p38 inhibitors |
US7626055B2 (en) | 2003-04-09 | 2009-12-01 | Smithkline Beecham Corporation | Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors |
US10047085B2 (en) | 2014-02-03 | 2018-08-14 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10399976B2 (en) | 2014-02-03 | 2019-09-03 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9624217B2 (en) | 2014-02-03 | 2017-04-18 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US11535614B2 (en) | 2014-02-03 | 2022-12-27 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10807980B2 (en) | 2014-02-03 | 2020-10-20 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9266886B2 (en) | 2014-02-03 | 2016-02-23 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9796710B2 (en) | 2014-10-14 | 2017-10-24 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10087184B2 (en) | 2014-10-14 | 2018-10-02 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of RORγ |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US11001583B2 (en) | 2014-11-05 | 2021-05-11 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
US10829448B2 (en) | 2015-08-05 | 2020-11-10 | Vitae Pharmaceuticals, Llc | Substituted benzoimidazoles as modulators of ROR-γ |
US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
US10829481B2 (en) | 2016-01-29 | 2020-11-10 | Vitae Pharmaceuticals, Llc | Benzimidazole derivatives as modulators of ROR-gamma |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10913739B2 (en) | 2017-07-24 | 2021-02-09 | Vitae Pharmaceuticals, LLC (121374) | Inhibitors of RORγ |
US11186573B2 (en) | 2017-07-24 | 2021-11-30 | Vitae Pharmaceuticals, Llc | Inhibitors of ROR gamma |
Also Published As
Publication number | Publication date |
---|---|
CA2248294A1 (en) | 1997-09-12 |
EP0885179A1 (en) | 1998-12-23 |
CN1212674A (en) | 1999-03-31 |
DE19608791A1 (en) | 1997-09-11 |
JP2000506149A (en) | 2000-05-23 |
KR19990087687A (en) | 1999-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997032832A1 (en) | Process for producing fluorinated aromatics and fluorinated nitrogen-containing hetero-aromatics | |
DE60122127T2 (en) | Ionic liquids derived from Lewis acids based on titanium, niobium, tantalum and antimony, and their use | |
EP1616863A1 (en) | Process for the preparation of fluorinated aromatic compounds | |
DE19548428C1 (en) | 2-alkylmerkapto-4- (trifluoromethyl) benzoic acid ester and a process for its preparation | |
DE10129057A1 (en) | Improved process for the production of aromatics containing fluorine | |
DE2812649A1 (en) | 2-PHENOXY-5-TRIFLUORMETHYLPYRIDINE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | |
EP0168344B1 (en) | Process for the preparation of alpha, alpha-difluoroalkyl phenyl ether derivatives | |
EP0302326B1 (en) | Process for preparing fluorinated and optionally also chlorinated benzotrifluorides, and benzotrifluorides | |
EP0556737B1 (en) | Process for the preparation of substituted 2,3-difluoro-pyridines | |
DE3236730A1 (en) | METHOD FOR PRODUCING BENZOXAZOLYL AND BENZTHIAZOLYLOXYPHENOXYPROPION ACID DERIVATIVES | |
DE10005853C1 (en) | Process for the preparation of bis- (4-amino-1-pyridinium) alkanes | |
EP0297352A1 (en) | (Azolyl-vinyl)-phenol-alkenylethers | |
DE19836698A1 (en) | Process for the preparation of fluorinated benzyl alcohols and aldehydes | |
EP0068260A2 (en) | Substituted phenoxypropionates, process for their preparation and their use as herbicides | |
DE102004024012A1 (en) | Process for the preparation of 5-bromo-2,2-difluorobenzo-1,3-dioxoles | |
EP0157225B1 (en) | Process for the production of benzimidazolyl, benzoxazolyl and benzothiazolyl oxyphenoxypropionate derivatives | |
EP0274023A1 (en) | Saccharine salt of substituted amines | |
EP0092111B1 (en) | 2,2-dihalogen-3,3-dimethyl-cyclopropane derivatives | |
EP0061629B1 (en) | Process for the preparation of substituted alpha-halopropionic acids and of their derivatives; substituted vinylidene chloride | |
EP0173153B1 (en) | Benzocondensed heterocyclic compounds containing fluor, process for their preparation and their use | |
EP0365914A2 (en) | Fluorine-containing acetophenones optionally halogenated in the CH3-group, and their preparation from fluorinated benzonitriles | |
EP0596395A1 (en) | Fluorinated benzils and process for their preparation | |
EP0445644B1 (en) | Trifluoro- respectively chlorodifluoromethoxy pyrimidines and process for their preparation | |
WO2005019154A1 (en) | METHOD FOR PRODUCING α-FLUOROMALONIC ACID DIALKYL ESTERS | |
EP0347692B1 (en) | Process for preparing fluor-substituted benzaldehydes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97192773.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP KR RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997905116 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2248294 Country of ref document: CA Ref document number: 2248294 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980707152 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1997905116 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980707152 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997905116 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019980707152 Country of ref document: KR |